Price T Rowe Associates Inc Vera Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,479,717 shares of VERA stock, worth $94.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,479,717
Previous 4,754,832
5.79%
Holding current value
$94.7 Million
Previous $114 Million
7.59%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding VERA
# of Institutions
199Shares Held
64.6MCall Options Held
1.58MPut Options Held
365K-
Avoro Capital Advisors LLC New York, NY6.3MShares$133 Million2.71% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.43MShares$72.4 Million9.64% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.35MShares$70.8 Million1.81% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$70.6 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY3.1MShares$65.5 Million3.85% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $572M
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...